8-K: Johnson & Johnson Reports Strong Q4 and Full-Year 2024 Results, Issues Positive 2025 Guidance

Johnson & Johnson announced a 5.3% increase in fourth-quarter sales and a 4.3% increase in full-year sales for 2024, alongside positive guidance for 2025.

Summary

• Johnson & Johnson reported a 5.3% increase in reported sales for the fourth quarter of 2024, reaching $22.5 billion, with operational growth of 6.7%.
• Full-year 2024 reported sales grew by 4.3% to $88.8 billion, with operational growth of 5.9%, and 7.0% excluding COVID-19 vaccine sales.
• Fourth-quarter earnings per share (EPS) were $1.41, and adjusted EPS was $2.04, both impacted by a $(0.22) charge related to acquired IPR&D from the V-Wave acquisition.
• Full-year EPS was $5.79, and adjusted EPS was $9.98, which included a $(0.67) charge due to acquired IPR&D charges throughout the year.
• The company's 2025 guidance projects operational sales growth of 2.5% to 3.5% and adjusted operational EPS of $10.75 to $10.95, reflecting strong growth of 8.7% at the mid-point.
• Innovative Medicine operational sales, excluding the COVID-19 vaccine, grew by 7.5% for the full year, driven by products like DARZALEX, ERLEADA, and CARVYKTI.
• MedTech operational sales grew by 6.2% for the full year, with acquisitions and divestitures contributing 1.5% to this growth.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong sales growth and a promising pipeline, but the decrease in net earnings and adjusted EPS, along with the VARIPULSE delay, temper the overall sentiment.

Positives

• The company experienced strong sales growth in both the fourth quarter and full year of 2024.
• The Innovative Medicine segment showed strong growth, particularly in oncology and immunology.
• The MedTech segment also demonstrated solid growth, driven by electrophysiology products and wound closure products.
• The company has a robust pipeline with significant progress in several key areas, including regulatory approvals and data releases.
• Johnson & Johnson issued positive guidance for 2025, indicating continued growth and profitability.
• The company's free cash flow is estimated to be approximately $19.8 billion for the full year.

Negatives

• Net earnings and EPS for both the fourth quarter and full year were negatively impacted by acquired IPR&D charges.
• Adjusted net earnings and adjusted EPS decreased in both the fourth quarter and full year compared to the previous year.
• The international sales growth was lower than the US sales growth.
• Currency fluctuations had a negative impact on sales growth.
• There were some declines in sales of certain products, such as STELARA in Immunology and some products in Neuroscience.

Risks

• The company faces risks related to economic factors, such as interest rate and currency exchange rate fluctuations.
• Competition, including technological advances and new products from competitors, poses a risk.
• There are inherent challenges in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals.
• The company faces uncertainty of commercial success for new and existing products.
• Patent challenges and expirations could impact revenue.
• The company's ability to execute strategic plans, including restructuring plans, is a risk.
• Manufacturing difficulties or delays, internally or within the supply chain, could impact results.
• Product efficacy or safety concerns could lead to recalls or regulatory action.
• Significant adverse litigation or government action, including product liability claims, could impact the company.
• Changes to applicable laws and regulations, including tax laws and global health care reforms, could pose a risk.
• Trends toward health care cost containment could impact revenue.
• Changes in behavior and spending patterns of purchasers of health care products and services could impact results.
• Financial instability of international economies and legal systems and sovereign risk could pose a risk.
• Increased scrutiny of the health care industry by government agencies could impact the company.
• The company's ability to realize the anticipated benefits from the separation of Kenvue Inc. is a risk.

Future Outlook

Johnson & Johnson anticipates continued growth in 2025, with operational sales growth projected between 2.5% and 3.5% and adjusted operational EPS between $10.75 and $10.95. The company expects strong growth of 8.7% at the mid-point for adjusted operational EPS.

Management Comments

• 2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation, said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson.
• As a healthcare company, with a disease-centric approach, we are improving the standard of care in a broad range of diseases with high unmet need, including multiple myeloma, lung cancer, inflammatory bowel disease, and heart failure.
• With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of Johnson & Johnson.

Industry Context

This announcement reflects Johnson & Johnson's continued focus on innovation and growth in the healthcare sector. The company's performance is being driven by key products in oncology, immunology, and cardiovascular, aligning with broader trends in these therapeutic areas. The company's focus on medical devices and robotics also positions it well in the evolving healthcare landscape.

Comparison to Industry Standards

• Johnson & Johnson's 5.3% Q4 sales growth is solid, but it is important to compare this to peers like Pfizer, which has seen significant fluctuations due to COVID-19 related sales, and AbbVie, which has been navigating patent expirations.
• The 7.5% growth in Innovative Medicine, excluding COVID-19 vaccine sales, is a strong indicator of the company's pipeline strength, especially when compared to companies like Merck, which also has a strong oncology portfolio.
• MedTech's 6.2% growth is competitive with other large medical device companies like Medtronic and Stryker, but it is important to note that Johnson & Johnson's growth includes a 1.5% boost from acquisitions and divestitures.
• The company's 2025 guidance for operational sales growth of 2.5% to 3.5% is a reasonable target, but it will be important to see how it compares to the guidance of other large healthcare companies.
• The adjusted EPS guidance of $10.75 to $10.95 reflects a strong growth of 8.7% at the mid-point, which is a positive sign for investors, but it is important to compare this to the EPS growth of other companies in the sector.

Stakeholder Impact

• Shareholders will be impacted by the financial results and future guidance.
• Employees will be impacted by the company's performance and strategic direction.
• Customers will benefit from the company's continued innovation and product development.
• Suppliers will be impacted by the company's purchasing decisions.
• Creditors will be impacted by the company's financial health and ability to repay debts.

Next Steps

• Johnson & Johnson will conduct a conference call with investors to discuss the earnings release.
• The company will continue to focus on product development and regulatory approvals.
• The company will provide further modeling considerations on the webcast.

Key Dates

Keywords

Johnson & Johnson, JNJ, Pharmaceuticals, MedTech, Healthcare, Earnings, Sales, Financial Results, EPS, Guidance, Innovation, Oncology, Immunology, Cardiovascular, Robotics, Regulatory Approvals